Table 2 Summary of primary and key secondary efficacy endpoint analyses at week 24.
Gecacitinib | HU | P value | |
|---|---|---|---|
(n = 71) | (n = 34) | ||
SVR35 rate assessed by IRC at week 24, % | 64.8 | 26.5 | 0.0002 |
TSS50 rate at week 24, % | 62 | 50 | 0.2065 |
Transfusion-dependent to independent, % | 16.7 | 0 | 0.4386 |
Non-transfusion-dependent baseline HGB ≤ 100 g/L exhibited a ≥20 g/L HGB increase, % | 31 | 15 | 0.1827 |
≥50% Reduction in transfusion frequency, % | 63.6 | 60 | >0.9999 |
≥50% Reduction in transfusion units, % | 54.5 | 40 | 0.4795 |
Mean absolute change in HGB at week 24, g/L | 1.27 | −3.5 | NA |
Mean absolute change in PLT at week 24, 109/L | −93.28 | −182.56 | NA |
Clinical improvement, % | 70.4 | 41.2 | NA |
